On Tuesday, Alto Neuroscience, Inc. (NYSE:ANRO) revealed that the Phase 2b study of ALTO-100 for major depressive disorder (MDD) did not meet its primary endpoint compared to placebo. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback